Catalysts / GPCR
Upcoming FDA decisions and readouts we track for Structure Therapeutics, each with the filing that announced it.
FreeBioList tracks 3 upcoming catalysts for Structure Therapeutics (GPCR, listed on Nasdaq). They cover 2 programmes: Aleniglipron (Type 2 diabetes with obesity or overweight; Obesity and overweight) and ACCG-2671 (Obesity).
First on the list: the Phase 2 readout for Aleniglipron (Type 2 diabetes with obesity or overweight), guided by the company to Q4 2026. The furthest-out event tracked is H2 2028. By stage, the upcoming rows are 1 Phase 1/2 readout, 1 Phase 2 readout and 1 Phase 3 readout.
All 3 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4; How to read a Phase 3 topline readout.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Structure Therapeutics GPCR · Nasdaq | Aleniglipron | Type 2 diabetes with obesity or overweight | Q4 2026 company guidance |
Phase 2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Structure Therapeutics GPCR · Nasdaq | ACCG-2671 | Obesity | H1 2027 company guidance |
Phase 1/2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Structure Therapeutics GPCR · Nasdaq | Aleniglipron | Obesity and overweight | H2 2028 company guidance |
Phase 3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList